Ruijia Chen

Fuzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5.

Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5.

Journal: Frontiers in public health
Published: April 04, 2025

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.

Journal: Frontiers in pharmacology
Published: June 10, 2023

Estimated Effects of Amyloid Reduction on Cognitive Change: A Bayesian Update across a Range of Priors.

Estimated Effects of Amyloid Reduction on Cognitive Change: A Bayesian Update across a Range of Priors.

Journal: medRxiv : the preprint server for health sciences
Published: May 19, 2023

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma.

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma.

Journal: Frontiers in pharmacology
Published: May 09, 2023

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.

Journal: Frontiers in pharmacology
Published: February 22, 2023

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.

Journal: Frontiers in pharmacology
Published: August 15, 2022

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.

Journal: Frontiers in oncology
Published: July 05, 2022

Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data.

Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data.

Journal: Journal of clinical pharmacology
Published: April 02, 2022

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.

Journal: Frontiers in pharmacology
Published: February 08, 2022

Explainable machine learning model for predicting spontaneous bacterial peritonitis in cirrhotic patients with ascites.

Explainable machine learning model for predicting spontaneous bacterial peritonitis in cirrhotic patients with ascites.

Journal: Scientific reports
Published: June 12, 2021

Developing a risk prediction model for multidrug-resistant bacterial infection in patients with biliary tract infection.

Developing a risk prediction model for multidrug-resistant bacterial infection in patients with biliary tract infection.

Journal: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
Published: August 10, 2020

Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.

Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 16, 2014
Showing 1-12 of 12

Last Updated: 09/26/2026